Curbstone Financial Management Corp lowered its position in Pfizer Inc. (NYSE:PFE) by 1.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 66,687 shares of the biopharmaceutical company’s stock after selling 800 shares during the period. Curbstone Financial Management Corp’s holdings in Pfizer were worth $2,416,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently modified their holdings of PFE. Kinloch Capital LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $25,000. Alpha DNA Investment Management LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $26,000. Penbrook Management LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $27,000. Orion Capital Management LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $29,000. Finally, Merrion Investment Management Co LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $30,000. Hedge funds and other institutional investors own 67.36% of the company’s stock.
PFE stock traded up $0.16 during midday trading on Thursday, reaching $36.07. 188,643 shares of the company’s stock traded hands, compared to its average volume of 32,556,707. The company has a market cap of $201.19 billion, a price-to-earnings ratio of 23.17, a P/E/G ratio of 2.79 and a beta of 0.70. The firm’s fifty day moving average price is $35.06 and its 200-day moving average price is $36.58. The company has a quick ratio of 1.13, a current ratio of 1.40 and a debt-to-equity ratio of 0.76. Pfizer Inc. has a 52 week low of $31.61 and a 52 week high of $43.08.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.46 by ($0.04). Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The firm had revenue of $11.68 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same quarter in the previous year, the company earned $0.55 EPS. The business’s revenue was up 11.8% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current year.
PFE has been the topic of a number of research reports. Berenberg Bank reiterated a “neutral” rating and set a $38.00 target price on shares of Pfizer in a research report on Tuesday, March 23rd. Morgan Stanley dropped their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Friday, January 29th. SVB Leerink dropped their target price on shares of Pfizer from $40.00 to $39.00 and set a “market perform” rating on the stock in a research report on Thursday, April 1st. The Goldman Sachs Group set a $41.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research report on Tuesday. Finally, TheStreet downgraded shares of Pfizer from a “b” rating to a “c+” rating in a research report on Friday, March 5th. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $38.47.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Further Reading: Momentum Investing
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.